Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 63, Issue 5, pp 911–918 | Cite as

The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population

  • Zhao-Hui Huang
  • Dong Hua
  • Li-Hua Li
Original Article

Abstract

Purpose

The aim of this study was to investigate the association of the thymidylate synthase (TS) and methylenetetrahydrofolate reductase (MTHFR) polymorphisms with the clinical outcomes of gastric cancer patients treated with 5-FU-based adjuvant chemotherapy.

Methods

One-hundred and sixteen patients with gastric cancer were treated with 5-FU-based adjuvant chemotherapy. The TS (a 28-bp tandem repeat polymorphism in the TS enhancer region (TSER) and a 6 bp deletion/insertion polymorphism in the 3′-untranslated region) and MTHFR C677T polymorphisms were determined in blood samples from those patients using PCR and PCR-LDR (ligation detection reaction) method, respectively.

Results

The overall survival (OS) in patients with the TS ins6/ins6 genotype was significantly shorter than those in patients with the del6/del6 (= 0.017) and ins6/del6 (= 0.022) genotype. The relapse-free survival (RFS) and OS in patients with the MTHFR C/C genotype were significantly worse than those in patients with the T/T or C/T genotype (= 0.043 and 0.040, respectively). Cox multivariate analysis also showed that patients with the TS ins6/ins6 genotype have worse OS than patients with the T/T or C/T genotype (HR = 2.437, = 0.041), and the MTHFR C/C genotype was associated with shorter RFS (HR = 1.723, = 0.031) and OS (HR = 1.681, = 0.056). No significant association was found between the TSER polymorphism and the clinical outcomes (> 0.05).

Conclusion

The polymorphisms of TS 3′-UTR ins6/del6 and MTHFR C677T appear to be potential prognostic factors in gastric cancer patients treated with 5-FU-based adjuvant chemotherapy, which may allow identification of gastric cancer patients who will benefit from 5-FU chemotherapy.

Keywords

Gastric cancer Adjuvant chemotherapy Polymorphism 5-Fluorouracil Thymidylate synthase Methylenetetrahydrofolate reductase 

Notes

Acknowledgments

This work was supported in part by a grant from the Scientific and Technologic Bureau of Wuxi (CLZ00612).

Supplementary material

280_2008_815_MOESM1_ESM.pdf (221 kb)
Supplementary Fig. 1 Genotyping results of the TS and MTHFR polymorphisms. A: Electrophoresis results of the TSER and TS 3′-UTR PCR products; B: Sequencing-verified results for the representative genotypes of TSER and TS 3′-UTR polymorphisms; C: Electrophoresis results of PCR-LDR products for MTHFR; D: Sequencing-verified result for the representative PCR products of MTHFR (PDF 220 kb)

References

  1. 1.
    Macdonald JS (2004) Treatment of localized gastric cancer. Semin Oncol 31:566–573PubMedCrossRefGoogle Scholar
  2. 2.
    Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V (2000) Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 11:837–843PubMedCrossRefGoogle Scholar
  3. 3.
    Hejna M, Wohrer S, Schmidinger M, Raderer M (2006) Postoperative chemotherapy for gastric cancer. Oncologist 11:136–145PubMedCrossRefGoogle Scholar
  4. 4.
    Carrato A, Gallego-Plazas J, Guillen-Ponce C (2005) Adjuvant therapy of resected gastric cancer is necessary. Semin Oncol 32:S105–S108PubMedCrossRefGoogle Scholar
  5. 5.
    Ishida Y, Kawakami K, Tanaka Y, Kanehira E, Omura K, Watanabe G (2002) Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Anticancer Res 22:2805–2809PubMedGoogle Scholar
  6. 6.
    Goekkurt E, Hoehn S, Wolschke C, Wittmer C, Stueber C, Hossfeld DK, Stoehlmacher J (2006) Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)–novel predictors for response and survival in gastric cancer patients. Br J Cancer 94:281–286PubMedCrossRefGoogle Scholar
  7. 7.
    Ott K, Vogelsang H, Marton N, Becker K, Lordick F, Kobl M, Schuhmacher C, Novotny A, Mueller J, Fink U, Ulm K, Siewert JR, Hofler H, Keller G (2006) The thymidylate synthase tandem repeat promoter polymorphism: a predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer. Int J Cancer 119:2885–2894PubMedCrossRefGoogle Scholar
  8. 8.
    Park DJ, Lenz HJ (2006) Determinants of chemosensitivity in gastric cancer. Curr Opin Pharmacol 6:337–344PubMedCrossRefGoogle Scholar
  9. 9.
    Hua D, Huang ZH, Mao Y, Deng JZ (2007) Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. World J Gastroenterol 13:5030–5034PubMedGoogle Scholar
  10. 10.
    Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, Yu L, Rosell R, Liu B (2008) ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 98:1398–1402PubMedCrossRefGoogle Scholar
  11. 11.
    Kawakami K, Omura K, Kanehira E, Watanabe Y (1999) Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19:3249–3252PubMedGoogle Scholar
  12. 12.
    Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J, Omura K, Watanabe G, Danenberg PV (2001) Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7:4096–4101PubMedGoogle Scholar
  13. 13.
    Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ, Ladner RD (2004) A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14:319–327PubMedCrossRefGoogle Scholar
  14. 14.
    Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE (2001) Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22:195–201PubMedCrossRefGoogle Scholar
  15. 15.
    Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI (2004) Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96:134–144PubMedCrossRefGoogle Scholar
  16. 16.
    Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R (2003) Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9:1611–1615PubMedGoogle Scholar
  17. 17.
    Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J (2005) Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23:1365–1369PubMedCrossRefGoogle Scholar
  18. 18.
    Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, Bisonni R, Canestrari E, Ficarelli R, Menichetti ET, Mari D, Testa E, Silva R, Vincenzi B, Giordani P, Cascinu S, Giustini L, Tonini G, Magnani M (2006) Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24:1883–1891PubMedCrossRefGoogle Scholar
  19. 19.
    Pare L, Altes A, Ramon y Cajal T, Del Rio E, Alonso C, Sedano L, Barnadas A, Baiget M (2007) Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy. Anticancer Drugs 18:821–825PubMedCrossRefGoogle Scholar
  20. 20.
    Huang ZH, Hua D, Li LH, Zhu JD (2008) Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. J Cancer Res Clin Oncol (in press)Google Scholar
  21. 21.
    Iacopetta B, Grieu F, Joseph D, Elsaleh H (2001) A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85:827–830PubMedCrossRefGoogle Scholar
  22. 22.
    Martinez-Balibrea E, Manzano JL, Martinez-Cardus A, Moran T, Cirauqui B, Catot S, Taron M, Abad A (2007) Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan. Oncol Rep 17:637–645PubMedGoogle Scholar
  23. 23.
    Lecomte T, Ferraz JM, Zinzindohoue F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P (2004) Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10:5880–5888PubMedCrossRefGoogle Scholar
  24. 24.
    Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25:1247–1254PubMedCrossRefGoogle Scholar
  25. 25.
    Dotor E, Cuatrecases M, Martinez-Iniesta M, Navarro M, Vilardell F, Guino E, Pareja L, Figueras A, Mollevi DG, Serrano T, de Oca J, Peinado MA, Moreno V, Germa JR, Capella G, Villanueva A (2006) Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 24:1603–1611PubMedCrossRefGoogle Scholar
  26. 26.
    Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344–354PubMedGoogle Scholar
  27. 27.
    Lu JW, Gao CM, Wu JZ, Cao HX, Tajima K, Feng JF (2006) Polymorphism in the 3′-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J Hum Genet 51:155–160PubMedCrossRefGoogle Scholar
  28. 28.
    Kawakami K, Graziano F, Watanabe G, Ruzzo A, Santini D, Catalano V, Bisonni R, Arduini F, Bearzi I, Cascinu S, Muretto P, Perrone G, Rabitti C, Giustini L, Tonini G, Pizzagalli F, Magnani M (2005) Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res 11:3778–3783PubMedCrossRefGoogle Scholar
  29. 29.
    Marcuello E, Altes A, del Rio E, Cesar A, Menoyo A, Baiget M (2004) Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112:733–737PubMedCrossRefGoogle Scholar
  30. 30.
    Marcuello E, Altes A, Menoyo A, Rio ED, Baiget M (2006) Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 57:835–840PubMedCrossRefGoogle Scholar
  31. 31.
    Lu JW, Gao CM, Wu JZ, Sun XF, Wang L, Feng JF (2004) Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-fluorouracil in gastric carcinoma. Ai Zheng 23:958–962PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Wuxi Oncology InstituteThe Fourth Affiliated Hospital of Suzhou UniversityWuxiChina

Personalised recommendations